- Oral presentation
- Open Access
Using the UK renal registry for a clinical trial in dialysis patients: the example of SIMPLIFIED
- Published: 16 November 2015
Keywords
- Cholecalciferol
- Dialysis Patient
- Kidney Failure
- Interventional Trial
- Routine Data
Kidney Failure confers a risk of death that exceeds that of most cancers. Interventions are urgently needed in this patient population. However, kidney failure patients are excluded from almost all interventional trials to avoid confounding, and trial results can therefore not easily be extrapolated. Trials in this population are challenging and expensive. Novel approaches to clinical trials are needed.
Vitamin D deficiency is highly prevalent in dialysis patients and is associated with increased mortality. Its supplementation in dialysis patients is safe.
Native Vitamin D (Cholecalciferol) is a low risk and provides the ideal test bed for novel trials methodologies.
The SIMPLIFIED trial is a large (n=4,200) pragmatic prospective randomised open-label blinded endpoint (PROBE) trial of cholecalciferol versus standard care in patients on dialysis. The primary endpoint is all-cause mortality, and secondary endpoints include CV events, infection, and cancer incidence.
SIMPLIFIED will have no dedicated trial visits, but will capture all data using routine data sources (ONS, HES, UK Renal Registry, PatientView). The UK Renal Registry (UKRR) captures detailed data on all UK dialysis patients, and undertakes linkage with HES and ONS. The UKRR also links with the patient portal PatientView, which allows renal patients to view and update their data.
Patients will consent to their data being directly accessible to the trial team via PatientView.
SIMPLIFIED will be the first UK nephrology trial to use routine data exclusively for trial follow-up, and should help develop expertise and infrastructure to carry out affordable clinical trials within the NHS.
Authors’ Affiliations
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.